Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 123 people in the sorafenib (Nexavar) group and 123 people in the placebo group — 246 participants in total. The trial was looking at ovarian cancer that had not yet progressed after initial treatment. The main thing it measured was how long participants went without their disease getting worse (called "progression-free survival"), based on scans or laboratory results. It also tracked a blood marker for ovarian cancer (CA-125), overall survival, and participants' self-reported symptom scores. The reported data shows that, for the main measure — time until disease progression or death — the sorafenib group had a median of 386 days, compared with 478 days in the placebo group. For the secondary measure of how long it took for the CA-125 blood marker to rise above normal, the sorafenib group recorded a median of 337 days, compared with 617 days in the placebo group. For overall survival (how long participants lived), the data was listed as "not available" for both groups, meaning those figures were not reported. Regarding the symptom questionnaire (scored from 0, meaning severely symptomatic, to 32, meaning no symptoms), both groups started at similar scores at the beginning of the trial (around 25.9 for sorafenib and 25.7 for placebo) and remained at similar levels by cycle 3, with only very small changes from baseline recorded in both groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23591401) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with advanced ovarian cancer (stage III or IV) or a related cancer called primary peritoneal cancer, confirmed by laboratory testing of tissue samples.
- After surgery to remove the tumor and 4 to 6 rounds of standard chemotherapy (using platinum and taxane-based drugs), all signs of cancer have completely disappeared on scans and tests.
- Your blood test for a cancer marker called CA125 is within the normal range, taken within 7 days before starting the study drug.
- You are generally well enough to carry out light activity and care for yourself (this is measured on a standard scale called ECOG, with a score of 0 or 1).
- Your scans confirming that the cancer is gone were done within 30 days before joining the trial.
- You are able to swallow and keep down tablets or capsules taken by mouth.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Any cancer tissue is still visible on a CT or MRI scan after completing chemotherapy.
- You have previously had radiotherapy to the area, chemotherapy before surgery, or chemotherapy given directly into the abdomen.
- Your ovarian cancer is not the epithelial type — for example, if it has been identified as sarcoma, lymphoma, or germ cell cancer.
- You have had major surgery, an open biopsy, or a serious physical injury within the 30 days before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment
Other options
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.